Breast cancer

16 November 2009

Study slows breast cancer spread

An experimental drug reduced the spread of breast cancer into bone in mice, researchers say.

This article has not necessarily been edited by Health24.

(HealthDay News) - An experimental drug reduced the spread of breast cancer into bone in mice, researchers say.

The drug -- Y27632 -- inhibits a protein called Rho-associated kinase (ROCK), which is over-produced in metastatic breast cancer. Inhibiting ROCK in the earliest stages of breast cancer reduced overall frequency of cancer spread (metastasis) by 36 percent and decreased metastatic tumor mass in bone by 77 percent, the researchers found.

The findings suggest that ROCK may prove to be a good target for new drug treatments to reduce the spread of breast cancer.

"While the primary tumor causes significant illness and requires treatment, metastasis accounts for over 90 percent of breast cancer-related deaths. There are no treatments to eradicate metastasis. Establishing ROCK's role in the spread of breast cancer and identifying agents to inhibit ROCK brings us one step closer to an approach that might reduce metastasis in the future," study senior author Dr. Michael Rosenblatt, professor of physiology and medicine at Tufts University School of Medicine, said in a university news release.

"We also found that using shRNA -- short hairpin RNA -- to knock down ROCK expression slowed metastasis. In order for cancer cells to migrate, an extensive transportation apparatus is required. ROCK directs the formation of this apparatus, but use of the ROCK inhibitor as well as shRNA rendered the cells' transportation mechanism ineffective, significantly reducing breast cancer metastasis to bone," study first author Sijin Liu, research instructor and member of the Rosenblatt Laboratory at Tufts, said in the news release.

"This study also revealed that a specific microRNA cluster, 17 through 92, is associated with ROCK expression and breast cancer metastasis. The microRNA cluster responded to ROCK inhibition, which provides insight into the mechanism driving metastasis and is a finding that will be of particular interest to researchers focused on the role of microRNAs in gene expression," Liu said.

The study was released online in advance of publication in the Nov. 15 print issue of the journal Cancer Research.

More information

The American Cancer Society has more about breast cancer.


Read Health24’s Comments Policy

Comment on this story
Comments have been closed for this article.

Ask the Expert

Breast cancer expert

Dr Gudgeon qualified in Birmingham, England, in 1968. She has more than 40 years experience in oncology, and in 1994 she founded her practice, Cape Breast Care, where she treats benign and malignant breast cancers. Dr Boeddinghaus obtained her qualification at UCT Medical School in 1994 and her MRCP in London in 1998. She has worked extensively in the field of oncology and has a special interest in the hormonal management of breast cancer. She now works with Dr Gudgeon at Cape Breast Care. Read more.

Still have a question?

Get free advice from our panel of experts

The information provided does not constitute a diagnosis of your condition. You should consult a medical practitioner or other appropriate health care professional for a physical exmanication, diagnosis and formal advice. Health24 and the expert accept no responsibility or liability for any damage or personal harm you may suffer resulting from making use of this content.

* You must accept our condition

Forum Rules